Imnoc25 mg

Imnoc 25 mg is indicated in- Depression. Panic disorder. Nocturnal enuresis.

Tricyclic & related anti-depressant drugs, Tricyclic Anti-depressant

Imnoc 25 mg works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter reducing the reuptake of norepinephrine and serotonin by neurons. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, producing knock-on effects in protein kinase signalling which is thought to contribute to changes in neurotransmission and brain physiology which relieves symptoms of depression.

Depression: Initially up to 75 mg daily in divided doses increased gradually to 150-200 mg (up to 300 mg in hospital); up to 150 mg may be given as a single dose at bed time; elderly, initially 10 mg daily, increased gradually to 30-50 mg daily; child not recommended for depression.Panic attack: Initially 10-25 mg/day, depending on how the medication is tolerated, raise the dose until the desired response is obtained. The daily doses required vary greatly from patient to patient, between 75-150 mg, if necessary it can be increased to 200 mg.Nocturnal enuresis (Child): 7 years: 25 mg 8 to 11 years: 20-50 mg  Over 11 years: 50-75 mg at bedtime; max. period of treatment (Including gradual withdrawal) is 3 months; full physical examination is required before further course.

Imnoc 25 mg should not be used in combination with Monoamine oxidase inhibitors (MAO), anticholinergic agents, antihypertensive agents, methylphenidate, levodopa, antipsychotic drug, cimetidine, barbiturates, and oral contraceptives.

Recent myocardial infarction, arrhythmias (particularly heart block), not indicated in manic phase, severe liver disease.

Dry mouth, less sedation, blurred vision (disturbances of accommodation, increased intraocular pressure), constipation, nausea, difficulty with micturation; cardiovascular side-effects, sweating, tremors, rashes and hypersensitivity reaction (including urticaria & photosensitivity), behavioral disturbances (particularly in children) hypomania or mania (particularly in elderly), interference with sexual function; blood sugar changes, increased appetite, weight gain (occasionally weight loss).

Treatment with Imnoc 25 mg should be avoided during pregnancy, unless the anticipated benefits justify the potential risk to the fetus. Since Imnoc 25 mg passes into the breast milk in small quantities, Imnoc 25 mg should be gradually withdrawn or the mother be advised to cease breast-feeding.

Cardiac diseases (particularly with arrhythmias), history with epilepsy, elderly, hepatic impairment (avoid if severe), thyroid disease, psychoses, angle-closure glaucoma, history of urinary retention, concurrent electro-convulsive therapy.

Children have been reported to be more sensitive than adults to an acute overdosage of Imnoc 25 mg. An acute overdose in infants or young children must be considered serious and potentially fatal.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.